Patents by Inventor Laurent Pradier

Laurent Pradier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190119365
    Abstract: Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide are provided. Methods of using antibodies specific to the protofibrillar form of the beta-amyloid peptide in the field of Alzheimer's disease are also provided.
    Type: Application
    Filed: September 26, 2018
    Publication date: April 25, 2019
    Inventors: Nicolas Baurin, Francis Blanche, Beatrice Cameron, Marc Duchesne, Vincent Mikol, Souad Naimi, Laurent Pradier, Yi Shi
  • Patent number: 10112991
    Abstract: Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide are provided. Methods of using antibodies specific to the protofibrillar form of the beta-amyloid peptide in the field of Alzheimer's disease are also provided.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: October 30, 2018
    Assignee: SANOFI
    Inventors: Nicolas Baurin, Francis Blanche, Beatrice Cameron, Marc Duchesne, Vincent Mikol, Souad Naimi, Laurent Pradier, Yi Shi
  • Publication number: 20160368977
    Abstract: The present application relates to humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide, and to the use of said antibodies in the field of Alzheimer's disease.
    Type: Application
    Filed: June 2, 2016
    Publication date: December 22, 2016
    Inventors: Nicolas Baurin, Francis Blanche, Beatrice Cameron, Marc Duchesne, Vincent Mikol, Souad Naimi, Laurent Pradier, Yi Shi
  • Publication number: 20160354445
    Abstract: The present invention refers to a pharmaceutical composition for use in the treatment of a neurodegenerative disease.
    Type: Application
    Filed: May 4, 2016
    Publication date: December 8, 2016
    Inventors: Sibylle HESS, Christian HOELSCHER, Andrees BOEHME, Agnes MENUT, Laurent PRADIER, Veronique TAUPIN
  • Patent number: 9382312
    Abstract: The present application relates to humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide, and to the use of said antibodies in the field of Alzheimer's disease.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: July 5, 2016
    Assignee: Sanofi
    Inventors: Nicolas Baurin, Francis Blanche, Beatrice Cameron, Marc Duchesne, Vincent Mikol, Souad Naimi, Laurent Pradier, Yi Shi
  • Patent number: 9364519
    Abstract: The present application relates to a pharmaceutical composition for use in the prevention or/and treatment of a neurodegenerative disease, the composition comprising desPro36Exendin-4(1-39)-Lys6-NH2 or/and a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, adjuvant, or/and auxiliary substance. In addition, the present application relates to the use of the pharmaceutical composition for the treatment and prevention of a neurodegenerative disease.
    Type: Grant
    Filed: September 4, 2012
    Date of Patent: June 14, 2016
    Assignees: SANOFI-AVENTIS DEUTSCHLAND GMBH, UNIVERSITY OF ULSTER
    Inventors: Sibylle Hess, Christian Hoelscher, Andrees Boehme, Agnes Menut, Laurent Pradier, Veronique Taupin
  • Publication number: 20140105890
    Abstract: The present application relates to humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide, and to the use of said antibodies in the field of Alzheimer's disease.
    Type: Application
    Filed: October 1, 2013
    Publication date: April 17, 2014
    Applicant: SANOFI
    Inventors: Nicolas BAURIN, Francis BLANCHE, Beatrice CAMERON, Marc DUCHESNE, Vincent MIKOL, Souad NAIMI, Laurent PRADIER, Yi SHI
  • Patent number: 8614299
    Abstract: The present application relates to humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide, and to the use of said antibodies in the field of Alzheimer's disease.
    Type: Grant
    Filed: May 11, 2010
    Date of Patent: December 24, 2013
    Assignee: Sanofi
    Inventors: Nicolas Baurin, Francis Blanche, Beatrice Cameron, Marc Duchesne, Vincent Mikol, Souad Naimi, Laurent Pradier, Yi Shi
  • Patent number: 8492610
    Abstract: The present invention relates to the field of transgenic animal models and more particularly the animal models of Alzheimer's disease. The invention relates to a transgenic animal expressing a multimutated form of presenilin 1 and allowing an apoptotic phenomenon to be detected in a renewable peripheral tissue.
    Type: Grant
    Filed: September 22, 2000
    Date of Patent: July 23, 2013
    Assignee: Aventis Pharma S.A.
    Inventors: Anne Eckert, Walter Muller, Christian Czech, Laurent Pradier, Gunter Tremp
  • Publication number: 20130116179
    Abstract: The present invention refers to a pharmaceutical composition for use in the treatment of a neurodegenerative disease.
    Type: Application
    Filed: September 4, 2012
    Publication date: May 9, 2013
    Applicants: UNIVERSITY OF ULSTER, SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Sibylle HESS, Christian HOELSCHER, Andrees BOEHME, Agnes MENUT, Laurent PRADIER, Veronique TAUPIN
  • Patent number: 8343493
    Abstract: A monoclonal antibody which specifically binds to the N-terminal region of A?8-x peptide, x being included from 11 to 42, and recognizes neither A?1-40 nor A?1-42 and which presents a high affinity with respect to A?8-x peptide, such as determined by an immunological complex formation between the monoclonal antibody and the peptide A?8-x.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: January 1, 2013
    Assignees: Innogenetics N.V., INSERM (Institut National de la Sante et de la Recherche Medicale), Sanofi
    Inventors: Eugeen VanMechelen, Pierre Grognet, Nicolas Sergeant, Marie Gompel, Andre Delacourte, Luc Buee, Laurent Pradier, Veronique Blanchard-Bregeon
  • Patent number: 8273548
    Abstract: The present invention relates to novel compounds and their uses, in particular their pharmaceutical or diagnostic uses or their use as pharmacological targets. More particularly, the present invention relates to a novel protein, referred to as PAP1, as well as to novel peptides and compounds which are capable of modulating, at least partially, the activity of parkin.
    Type: Grant
    Filed: March 28, 2006
    Date of Patent: September 25, 2012
    Assignee: Aventis Pharma S.A.
    Inventors: Han Koutnikova, Alexis Brice, Alain Fournier, Laurent Pradier, Catherine Prades, Isabelle Arnould-Reguigne, Marie-Françoise Rosier-Montus, Olga Corti
  • Publication number: 20120177639
    Abstract: The present application relates to humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide, and to the use of said antibodies in the field of Alzheimer's disease.
    Type: Application
    Filed: May 11, 2010
    Publication date: July 12, 2012
    Applicant: SANOFI
    Inventors: Nicolas Baurin, Francis Blanche, Beatrice Cameron, Marc Duchesne, Vincent Mikol, Souad Naimi, Laurent Pradier, Yi Shi
  • Publication number: 20110059092
    Abstract: The present invention relates to a monoclonal antibody which specifically binds to the N-terminal region of A?8-x peptide, x being comprised from 11 to 42, and recognises neither A?1-40 nor A?1-42 and which presents a high affinity with respect to A?8-x peptide, such as determined by an immunological complex formation between the monoclonal antibody and the peptide A?8-x.
    Type: Application
    Filed: October 24, 2008
    Publication date: March 10, 2011
    Applicants: INNOGENETICS NV, SANOFI-AVENTIS
    Inventors: Eugeen Vanmechelen, Pierre Grognet, Nicolas Sergeant, Marie Gompel, Andre Delacourte, Luc Buee, Laurent Pradier, Veronique Blanchard-bregeon
  • Patent number: 7803538
    Abstract: The present invention relates to a method for diagnosing an individual for early onset Alzheimer's disease by measuring the presence or absence of the minor allele of the rs908832 polymorphism of the ABCA2 gene. The presence of the minor allele of the rs908832 polymorphism of the ABCA2 gene indicates that the individual may be suffering from Alzheimer's disease or exhibits an increased risk of developing Alzheimer's disease.
    Type: Grant
    Filed: June 17, 2004
    Date of Patent: September 28, 2010
    Assignee: Aventis Pharma SA
    Inventors: Sandrine Mace, Sylvain Ricard, Emmanuelle Cousin, Laurent Pradier, Jésus Benavides, Jean-François Deleuze
  • Patent number: 7700823
    Abstract: The present invention relates to nonhuman transgenic animals exhibiting major disorders related to Alzheimer's disease. The animals can be used for demonstrating compounds intended for the treatment of Alzheimer's disease.
    Type: Grant
    Filed: October 1, 2004
    Date of Patent: April 20, 2010
    Assignee: Aventis Pharma S.A.
    Inventors: Caty Casas Louzao, Patrick Benoit, Laurent Pradier, Gunter Tremp, Jean-Michel Itier, Véronique Blanchard-Bregeon
  • Publication number: 20060287230
    Abstract: The present invention relates to novel compounds and their uses, in particular their pharmaceutical or diagnostic uses or their use as pharmacological targets. More particularly, the present invention relates to a novel protein, referred to as PAP1, as well as to novel peptides and compounds which are capable of modulating, at least partially, the activity of parkin.
    Type: Application
    Filed: March 28, 2006
    Publication date: December 21, 2006
    Inventors: Hana Koutnikova, Alexis Brice, Alain Fournier, Laurent Pradier, Catherine Prades, Isabelle Arnould-Reguigne, Marie-Francoise Rosier-Montus, Olga Corti
  • Patent number: 7132396
    Abstract: The present invention relates to novel compounds and their uses, in particular their pharmaceutical or diagnostic uses or their use as pharmacological targets. More particularly, the present invention relates to a novel protein, referred to as PAP1, as well as to novel peptides and compounds which are capable of modulating, at least partially, the activity of parkin.
    Type: Grant
    Filed: February 20, 2001
    Date of Patent: November 7, 2006
    Assignee: Aventis Pharma S.A.
    Inventors: Hana Koutnikova, Alexis Brice, Alain Fournier, Laurent Pradier, Catherine Prades, Isabelle Arnould-Reguigne, Marie-Françoise Rosier-Montus, Olga Corti
  • Patent number: 7070940
    Abstract: The present invention relates to a method for determining the ability of a compound to modify the interaction between parkin and the p38 protein, and in particular to a method for screening for or detecting compounds intended for the prevention and/or treatment of neurodegenerative pathological conditions. The present inventions also relates to compounds identified in the above screening method.
    Type: Grant
    Filed: July 18, 2003
    Date of Patent: July 4, 2006
    Assignee: Aventis Pharma S.A.
    Inventors: Olga Corti, Cornelia Hampe, Alexis Brice, Laurent Pradier, Thomas Rooney, Alain Fournier
  • Publication number: 20050076400
    Abstract: The present invention relates to nonhuman transgenic animals exhibiting major disorders related to Alzheimer's disease. The animals can be used for demonstrating compounds intended for the treatment of Alzheimer's disease.
    Type: Application
    Filed: October 1, 2004
    Publication date: April 7, 2005
    Applicant: Aventis Pharma S. A.
    Inventors: Caty Casas Louzao, Patrick Benoit, Laurent Pradier, Gunter Tremp, Jean-Michel Itier, Veronique Blanchard-Bregeon